Search Result

Results for "

myeloid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Cytotoxin (4) ADC Linker (1) AMPK (1) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (3) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (77) Arenavirus (1) Aurora Kinase (3) Autophagy (8) Bacterial (6) Bcl-2 Family (19) Bcr-Abl (14) Beta-lactamase (1) Biochemical Assay Reagents (2) Btk (4) c-Kit (1) c-Myc (2) Caspase (4) CD3 (3) CDK (9) Checkpoint Kinase (Chk) (1) ClpP (1) Complement System (2) COX (1) CRM1 (2) CXCR (2) Cyclic GMP-AMP Synthase (1) Dihydroorotate Dehydrogenase (9) DNA Alkylator/Crosslinker (2) DNA Methyltransferase (5) DNA/RNA Synthesis (6) Drug Metabolite (2) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (4) Endogenous Metabolite (5) Epigenetic Reader Domain (18) ERK (2) Eukaryotic Initiation Factor (eIF) (1) FLT3 (39) Fungal (1) Glutathione Peroxidase (1) GSK-3 (4) HDAC (14) Histone Acetyltransferase (1) Histone Demethylase (10) Histone Methyltransferase (3) HIV (1) HSP (1) Integrin (2) Interleukin Related (3) Isocitrate Dehydrogenase (IDH) (4) Isotope-Labeled Compounds (1) JAK (2) KLF (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (2) MAP4K (2) MDM-2/p53 (3) MEK (1) Mitochondrial Metabolism (3) Mitophagy (3) MMP (1) MNK (1) Molecular Glues (1) Monoamine Oxidase (1) mTOR (2) MyD88 (1) NF-κB (2) NOD-like Receptor (NLR) (1) Oxidative Phosphorylation (3) P-glycoprotein (2) p38 MAPK (1) Parasite (2) PDGFR (5) PGE synthase (1) PI3K (3) Pim (4) PROTACs (12) Proteasome (1) RAR/RXR (1) Reactive Oxygen Species (1) RET (2) Ribosomal S6 Kinase (RSK) (1) Salt-inducible Kinase (SIK) (2) SHP2 (1) Sialyltransferase (1) Src (2) STAT (6) Syk (1) TAM Receptor (1) TET Protein (1) Tim3 (1) TNF Receptor (3) Toll-like Receptor (TLR) (8) Topoisomerase (3) Trk Receptor (1) VEGFR (3)
By Research Areas:	Cancer (249) Cardiovascular Disease (4) Endocrinology (1) Infection (10) Inflammation/Immunology (33) Metabolic Disease (3) Neurological Disease (9)

By Targets:

ADC Antibody (1)

ADC Cytotoxin (4)

ADC Linker (1)

AMPK (1)

Anaplastic lymphoma kinase (ALK) (1)

Antibiotic (3)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (77)

Arenavirus (1)

Aurora Kinase (3)

Autophagy (8)

Bacterial (6)

Bcl-2 Family (19)

Bcr-Abl (14)

Beta-lactamase (1)

Biochemical Assay Reagents (2)

Btk (4)

c-Kit (1)

c-Myc (2)

Caspase (4)

CD3 (3)

CDK (9)

Checkpoint Kinase (Chk) (1)

ClpP (1)

Complement System (2)

COX (1)

CRM1 (2)

CXCR (2)

Cyclic GMP-AMP Synthase (1)

Dihydroorotate Dehydrogenase (9)

DNA Alkylator/Crosslinker (2)

DNA Methyltransferase (5)

DNA/RNA Synthesis (6)

Drug Metabolite (2)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (4)

Endogenous Metabolite (5)

Epigenetic Reader Domain (18)

ERK (2)

Eukaryotic Initiation Factor (eIF) (1)

FLT3 (39)

Fungal (1)

Glutathione Peroxidase (1)

GSK-3 (4)

HDAC (14)

Histone Acetyltransferase (1)

Histone Demethylase (10)

Histone Methyltransferase (3)

HIV (1)

HSP (1)

Integrin (2)

Interleukin Related (3)

Isocitrate Dehydrogenase (IDH) (4)

Isotope-Labeled Compounds (1)

JAK (2)

KLF (1)

Ligands for E3 Ligase (1)

Ligands for Target Protein for PROTAC (2)

MAP4K (2)

MDM-2/p53 (3)

MEK (1)

Mitochondrial Metabolism (3)

Mitophagy (3)

MMP (1)

MNK (1)

Molecular Glues (1)

Monoamine Oxidase (1)

mTOR (2)

MyD88 (1)

NF-κB (2)

NOD-like Receptor (NLR) (1)

Oxidative Phosphorylation (3)

P-glycoprotein (2)

p38 MAPK (1)

Parasite (2)

PDGFR (5)

PGE synthase (1)

PI3K (3)

Pim (4)

PROTACs (12)

Proteasome (1)

RAR/RXR (1)

Reactive Oxygen Species (1)

RET (2)

Ribosomal S6 Kinase (RSK) (1)

Salt-inducible Kinase (SIK) (2)

SHP2 (1)

Sialyltransferase (1)

Src (2)

STAT (6)

Syk (1)

TAM Receptor (1)

TET Protein (1)

Tim3 (1)

TNF Receptor (3)

Toll-like Receptor (TLR) (8)

Topoisomerase (3)

Trk Receptor (1)

VEGFR (3)

By Research Areas:

Cancer (249)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (10)

Inflammation/Immunology (33)

Metabolic Disease (3)

Neurological Disease (9)

282

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100688

ML390	Dihydroorotate Dehydrogenase	Cancer
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .

HY-P99014

Cusatuzumab 1 Publications Verification	Apoptosis	Inflammation/Immunology
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .

HY-148813

AK-2292	PROTACs STAT	Cancer
AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC₅₀ of 0.10 μM. AK-2292 induces degradation of STAT5A/B proteins in vitro and in vivo. AK-2292 can induce tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models . AK-2292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152036

SIAIS100

PROTACs Bcr-Abl Cancer

SIAIS100 is a potent BCR-ABL PROTAC degrader with an DC₅₀ value of 2.7 nM. SIAIS100 can be used to research chronic myeloid leukemia (CML) .
HY-162008

S1g-10

HSP Bcl-2 Family Cancer

S1g-10 is a Hsp70/Bim inhibitor, and shows antitumor activity in chronic myeloid leukemia cells .

SIAIS100	PROTACs Bcr-Abl	Cancer
SIAIS100 is a potent BCR-ABL PROTAC degrader with an DC₅₀ value of 2.7 nM. SIAIS100 can be used to research chronic myeloid leukemia (CML) .

S1g-10	HSP Bcl-2 Family	Cancer
S1g-10 is a Hsp70/Bim inhibitor, and shows antitumor activity in chronic myeloid leukemia cells .

HY-163328

DHODH-IN-25	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-25 (Compound 25) is an orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 5.4 nM for human DHODH. DHODH-IN-25 can be used for the study of acute myeloid leukemia (AML) .

HY-145620

Zuvotolimod	ADC Linker	Inflammation/Immunology Cancer
Zuvotolimod is a myeloid cell agonist compound-linker for antibody conjugate. Zuvotolimod can be used in the research of cancer and hepatitis .

HY-P99971

Gemtuzumab	ADC Antibody	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

HY-152036A

SIAIS100 TFA	PROTACs Bcr-Abl	Cancer
SIAIS100 TFA is a potent BCR-ABL PROTAC degrader with an DC₅₀ value of 2.7 nM. SIAIS100 TFA can be used to research chronic myeloid leukemia (CML) .

HY-134836

STM2457 15+ Cited Publications	Apoptosis	Cancer
STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC₅₀ of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML) .

HY-128068

DHODH-IN-17	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor (IC₅₀=0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML) .

HY-110071

APcK110

c-Kit Cancer

APcK110 is a potent Kit inhibitor that can be used for the research of acute myeloid leukemia (AML). APcK110 induces AML cell apoptosis .

APcK110	c-Kit	Cancer
APcK110 is a potent Kit inhibitor that can be used for the research of acute myeloid leukemia (AML). APcK110 induces AML cell apoptosis .

HY-146002

IDH2R140Q-IN-1	Isocitrate Dehydrogenase (IDH)	Cancer
IDH2R140Q-IN-1 (compound C6) is a potent inhibitor of IDH2 ^R140Q, with an IC₅₀ of 6.1 nM. IDH2R140Q-IN-1 can be used for the research of acute myeloid leukemia .

HY-160174

BCR-ABL kinase-IN-3

Bcr-Abl Cancer

BCR-ABL kinase-IN-3 (example 1) is a potent inhibitor of BCR-ABL that plays an important role in acute myeloid leukemia (AML) research .

BCR-ABL kinase-IN-3	Bcr-Abl	Cancer
BCR-ABL kinase-IN-3 (example 1) is a potent inhibitor of BCR-ABL that plays an important role in acute myeloid leukemia (AML) research .

HY-135664

hDHODH-IN-5	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-7 is a human dihydroorotate dehydrogenase (DHODH) inhibitor, with an IC₅₀ of 0.91 μM. DHODH-IN-7 induces differentiation in acute myeloid leukemia .

HY-160174A

BCR-ABL kinase-IN-3 (dihydrocholide)	Bcr-Abl	Cancer
BCR-ABL kinase-IN-3 (dihydrocholide) (example 1) is a potent inhibitor of BCR-ABL that plays an important role in acute myeloid leukemia (AML) research .

HY-148036

FLT3-IN-16

FLT3 Cancer

FLT3-IN-16 is a potent FLT3 inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

FLT3-IN-16	FLT3	Cancer
FLT3-IN-16 is a potent FLT3 inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

HY-128888B

(S,R)-GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
(S,R)-GSK321 is a potent, selective mutant IDH1 inhibitor with IC₅₀ values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. (S,R)-GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. (S,R)-GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .

HY-141677

INCB059872	Histone Demethylase	Cancer
INCB059872 is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 can be used for the research of myeloid leukemia .

HY-141677A

INCB059872 dihydrochloride	Histone Demethylase	Cancer
INCB059872 dihydrochloride is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 dihydrochloride can be used for the research of myeloid leukemia .

HY-157134

Y08262	Others	Cancer
Y08262 is a potent and selective CBP bromodomain inhibitor. Y08262 selectively inhibits the CBP bromodomain with an IC₅₀ value of 73.1 nM. Y08262 can be used for the research of acute myeloid leukemia (AML) .

HY-154961

Mcl-1 inhibitor 14	Bcl-2 Family	Cancer
Mcl-1 inhibitor 14 (Compound (Ra)-10) is an inhibitor of myeloid cell leukemia-1 (MCL-1) with an K_i of 0.018 nM and can be used for anticancer research .

HY-N0564

Notopterol 1 Publications Verification	Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Notopterol is a coumarin extracted from N. incisum. Notopterol induces apoptosis and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML) .

HY-139535

Luxeptinib CG-806	FLT3 Btk Apoptosis	Cancer
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells .

HY-108969

Pyrazoloacridine NSC 366140; PD 115934	Topoisomerase Apoptosis	Cancer
Pyrazoloacridine (NSC 366140), an intercalating agent with anti-cancer activity, inhibits the activity of topoisomerases 1 and 2. Pyrazoloacridine (NSC 366140) exhibits an IC₅₀ of 1.25 μM in K562 myeloid leukemia cells for 24 h treatment .

HY-112218

MIK665 5+ Cited Publications S-64315	Bcl-2 Family	Cancer
MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor . MIK665 has an IC₅₀ of 1.81 nM for MCL1 .

HY-101150

DGN462	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .

HY-101150A

sulfo-DGN462 sodium	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
sulfo-DGN462 sodium is degraded to DGN462 in culture medium and plasma. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML) .

HY-124629

DB2313	Apoptosis	Cancer
DB2313 is a potent transcription factor PU.1 inhibitor with an apoptosis of 14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects .

HY-109117

Iadademstat ORY-1001	Histone Demethylase	Cancer
Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research .

HY-141680

CPS2 1 Publications Verification	PROTACs CDK	Cancer
CPS2 is a first-in-class, highly potent, selective and irreversible PROTAC CDK2 degrader (IC₅₀= 24 nM). CPS2 can be used for the research of acute myeloid leukemia .

HY-151634

Syk-IN-6	Syk STAT ERK	Cancer
Syk-IN-6 is an inhibitor of the lipid-SH2 domain interaction, control the cellular activity of kinases containing SH2 domain. Syk-IN-6 blocks Syk kinase activity, which associated hematopoietic malignancies, including acute myeloid leukemia (AML) .

HY-161149

CM-1758	HDAC	Cancer
CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells .

HY-101266B

Milademetan tosylate hydrate 2 Publications Verification DS-3032b; DS-3032 tosylate hydrate	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis .

HY-109184

Murizatoclax AMG 397	Bcl-2 Family	Cancer
Murizatoclax (AMG 397) is a potent, selective and orally active inhibitor of myeloid leukemia 1 (MCL-1) inhibitor, with a K_i of 15 pM. Murizatoclax competitive binds to the BH3-binding groove of MCL1 with pro-apoptotic BCL-2 family members. Murizatoclax can be used for the research of cancer .

HY-129592

p-Tolylmaleimide	Apoptosis	Cancer
p-Tolylmaleimide (compound 9) is a naphthalimide derivative that has cytotoxic effects on cancer cells. p-Tolylmaleimide can arrest the cell cycle of human acute myeloid leukemia cells K562 in the sub-G0/G1 phase and induce apoptosis .

HY-120395

UC-514321	STAT Apoptosis TET Protein	Inflammation/Immunology Cancer
UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity .

HY-P99521

Vibecotamab XmAb14045	CD3	Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .

HY-151560

hDHODH-IN-11	Dihydroorotate Dehydrogenase	Cancer
hDHODH-IN-11 is a potent human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC₅₀ value of 7.2 nM. hDHODH-IN-11 has low cytotoxicity. hDHODH-IN-11 can be used in research of acute myeloid leukemia (AML) .

HY-149981

P-gp inhibitor 13	P-glycoprotein	Cancer
P-gp inhibitor 13 is a P-gp inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .

HY-109539

Gemtuzumab ozogamicin	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic drug Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML) .

HY-149030

DHODH-IN-21	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-21 (compound 19) is an orally active selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 1.1 nM. DHODH-IN-21 has anticancer activity and can be used in studies of acute myeloid leukaemia (AML) .

HY-153857

PHI-101	FLT3	Cancer
PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML) .

HY-124676A

DB2115 tertahydrochloride 1 Publications Verification	Apoptosis	Cancer
DB2115 (tertahydrochloride) is a potent inhibitor of myeloid master regulator PU.1. DB2115 (tertahydrochloride) has the potential for researching cancers, including hematologic cancers such as leukemia, as well as other conditions associated with PU. 1 dysfunction (extracted from patent WO2017223260A1, compound DB2115) .

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val) Cyclo(RGDfV); C(RGDfV)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .

HY-N10079

Suchilactone Jatrophan	SHP2	Cancer
Suchilactone (Jatrophan) is a lignan extracted from Monsonia angustifolia E.Mey. Suchilactone binds to SHP2 and inhibits SHP2 activation, thereby inhibiting ERK-mediated cell proliferation. Suchilactone can be ued in acute myeloid leukaemia (AML) .

HY-16379A

Pacritinib hydrochloride SB1518 hydrochloride	JAK FLT3	Cancer
Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .

HY-136175

Revumenib 5+ Cited Publications SNDX-5613	Epigenetic Reader Domain	Cancer
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

HY-138831

AES-350	HDAC Apoptosis	Cancer
AES-350 is a potent and orally active HDAC6 inhibitor with an IC₅₀ and a K_i of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC₅₀ values of 0.187 μM and 0.245 μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research .

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

Cat. No.	Product Name	Target	Research Area

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

HY-P3508

PNC-27

Peptides Cancer

PNC-27 is an anticancer peptide, containing an HDM-2-binding domain. PNC-27 shows anti-tumor activity and can be used in acute myeloid leukemia research .

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val) Cyclo(RGDfV); C(RGDfV)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .

HY-P5117

TAT-CIRP	Toll-like Receptor (TLR)	Neurological Disease
TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice .

HY-P5474

PMAP-23

Bacterial Others

PMAP-23 is a biological active peptide. (an antimicrobial peptide (AMP) derived from porcine myeloid.)

HY-P3400

LQVTDSGLYRCVIYHPP	Peptides	Neurological Disease
LQVTDSGLYRCVIYHPP (LP17) is a triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LQVTDSGLYRCVIYHPP substantially alleviates ischemia-induced infarction and neuronal injury. LQVTDSGLYRCVIYHPP can get access into brain and block TREM-1 .

HY-P3400A

LQVTDSGLYRCVIYHPP TFA	Peptides	Neurological Disease
LQVTDSGLYRCVIYHPP (LP17) TFA is a triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LQVTDSGLYRCVIYHPP TFA substantially alleviates ischemia-induced infarction and neuronal injury. LQVTDSGLYRCVIYHPP TFA can get access into brain and block TREM-1 .

HY-P5484

SMAP-18	Bacterial	Others
SMAP-18 is a biological active peptide. (SMAP-18 is a 18-amino acid residue peptide amide which is a truncated form of SMAP-29. Sheep myeloid antimicrobial peptide-29 (SMAP-29) displays extremely high antimicrobial activity against Pseudomonas strains, other Gram-negative bacteria, and multidrug-resistant pathogens. SMAP-18 displays much higher cell selectivity as compared to parental SMAP-29 because of its decreased hemolytic activity and retained antimicrobial activity.)

HY-P5446

BMAP-18	Bacterial	Others
BMAP-18 is a biological active peptide. (BMAP-18 is a truncated form of the antimicrobial peptide BMAP-27. Bovine myeloid antimicrobial peptide-27 (BMAP-27) belongs to the Cathelicidin family of peptides which displays rapid bactericidal activity against Staphylococcus aureus, Streptococcus uberis, and Escherichia coli. BMAP-27 is cytotoxic to human erythrocytes and neutrophils, although at higher than microbicidal concentrations. BMAP-18 displays much higher cell selectivity as compared to parental BMAP-27 because of its decreased hemolytic activity and retained antimicrobial activity.)

HY-P10136A

IA9 TFA human TREM-2 182-190 TFA	Peptides	Inflammation/Immunology
IA9 TFA (human TREM-2 182-190 TFA) is a TREM-2 inhibitor , and can diminish release of proinflammatory cytokines and dramatically suppressed joint inflammation and damage in collagen-Induced Arthritis (CIA) mice model .

HY-P10136

IA9 human TREM-2 182-190	Peptides	Inflammation/Immunology
IA9 (human TREM-2 182-190) is a TREM-2 inhibitor , and can diminish release of proinflammatory cytokines and dramatically suppressed joint inflammation and damage in collagen-Induced Arthritis (CIA) mice model .

Cat. No.	Product Name	Target	Research Area

HY-P99014

Cusatuzumab 1 Publications Verification	Apoptosis	Inflammation/Immunology
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .

HY-P99971

Gemtuzumab	ADC Antibody	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

HY-P99044

Sabatolimab MBG453	Tim3	Inflammation/Immunology
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .

HY-P99958

Vixtimotamab AMV-564; TandAb T564	Inhibitory Antibodies	Cancer
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .

HY-P99521

Vibecotamab XmAb14045	CD3	Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .

HY-P99390

Tepoditamab MCLA 117	CD3	Cancer
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .

HY-P990043

Iluzanebart

Inhibitory Antibodies Cancer

Iluzanebart is a human IgG1κ antibody targeting TREM2, a triggering receptor expressed on myeloid cells .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-P99742

Mitazalimab ADC-1013; JNJ-64457107	TNF Receptor	Cancer
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .

HY-P99272

Ulocuplumab BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P9948

Alemtuzumab Campath-IH	Apoptosis	Cancer
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0564

Notopterol 1 Publications Verification	Classification of Application Fields Neurological Disease Isodon excisoides (Sun ex C. H. Hu) H. Hara Source classification Coumarins Phenylpropanoids Plants Umbelliferae Disease Research Fields Inflammation/Immunology	Apoptosis
Notopterol is a coumarin extracted from N. incisum. Notopterol induces apoptosis and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML) .

HY-13680

Meisoindigo Dian III; N-Methylisoindigotin; Natura-α	Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Cancer	Apoptosis
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .

HY-N2517

Dihydroevocarpine	Alkaloids Classification of Application Fields Source classification Evodia rutaecarpa (Juss.) Benth. Rutaceae Quinoline Alkaloids Plants Disease Research Fields Cancer	mTOR
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity .

HY-N10079

Suchilactone Jatrophan	Structural Classification Polygala chinensis Linnaeus Source classification Polygalaceae Lignans Phenylpropanoids Plants	SHP2
Suchilactone (Jatrophan) is a lignan extracted from Monsonia angustifolia E.Mey. Suchilactone binds to SHP2 and inhibits SHP2 activation, thereby inhibiting ERK-mediated cell proliferation. Suchilactone can be ued in acute myeloid leukaemia (AML) .

HY-123121

Nargenicin A1	Infection Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Inflammation/Immunology Disease Research Fields Cancer	Antibiotic Apoptosis Bacterial NF-κB
Nargenicin A1 is an antibiotic agent against various Gram-positive bacteria. Nargenicin A1 shows anti-inflammatory activity. Nargenicin A1 protects HINAE cells against Tacrolimus (HY-13756)-induced DNA damage and apoptosis. Nargenicin A1 can also be used for the research of acute myeloid leukemia .

HY-N3210

Nb-Demethylechitamine	Apocynaceae Structural Classification Alkaloids Source classification Plants Indole Alkaloids Alstonia rostrata C. E. C. Fischer	Others
Nb-Demethylechitamine is an alkaloid isolated from the methanol extract of Alstonia rostrata twigs. Nb-Demethylechitamine has in vitro cytotoxic activity against several human cancer cell lines, including human myeloid leukemia HL-60, liver cancer SMMC-7721, lung cancer A-549, breast cancer MCF-7, and colon cancer SW480 cells .

HY-N0774

Isofraxidin 1 Publications Verification	Structural Classification Monophenols Classification of Application Fields Source classification Coumarins Phenols Phenylpropanoids Acanthopanax senticosus (Rupr. et Maxim.) Harms Plants Inflammation/Immunology Disease Research Fields Araliaceae	COX MMP Toll-like Receptor (TLR)
Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits MMP-7 expression and cell invasion of human hepatoma cells. Isofraxidin inhibits the phosphorylation of ERK1/2 in hepatoma cells . Isofraxidin attenuates the expression of iNOS and COX-2, Isofraxidinalso inhibits *TLR4*/myeloid differentiation protein-2 (MD-2) complex formation .

HY-116894

Rotundifuran	Classification of Application Fields Terpenoids Tephrosia villosa (L.) Pers. Source classification Diterpenoids Plants Compositae Disease Research Fields Cancer	Apoptosis
Rotundifuran, a labdane type diterpene, is isolated from Vitex rotundifolia. Rotundifuran can inhibit the cell cycle progression and induce apoptosis in human myeloid leukaemia cells .

HY-N0071

Crotonoside Isoguanosine	Alkaloids Structural Classification Classification of Application Fields Croton tiglium Linn. Source classification Euphorbiaceae Plants Disease Research Fields Cancer	FLT3 HDAC
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-N2492

(E)-Methyl 4-coumarate Methyl trans-p-coumarate	Infection Monophenols Classification of Application Fields Source classification Rubiaceae Morinda citrifolia Linn. Other Phenylpropanoids Phenols Phenylpropanoids Plants Disease Research Fields	Bacterial Apoptosis
(E)-Methyl 4-coumarate (Methyl 4-hydroxycinnamate), found in several plants, such as Allium cepa or Morinda citrifolia L. leaves. (E)-Methyl 4-coumarate cooperates with Carnosic Acid in inducing apoptosis and killing acute myeloid leukemia cells, but not normal peripheral blood mononuclear cells. Antioxidant and antimicrobial activity.

HY-13653

(-)-Epigallocatechin Gallate Maximum Cited Publications 29 Publications Verification EGCG; Epigallocatechol Gallate	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Flavonoids other families Flavonones Phenols Polyphenols Inflammation/Immunology Disease Research Fields Cancer	Endogenous Metabolite Apoptosis
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-113455

9S-HODE Alpha-dimorphecolic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Apoptosis Endogenous Metabolite
9S-HODE (Alpha-dimorphecolic acid) is an octadecadienoic acid and the main active derivative of linoleic acid, which can reduce the viability of HL-60 cells and induce apoptosis. 9S-HODE is rich in lipid peroxidation (LPO) products and is almost an ideal marker for LPO .

HY-150526

EGCG-4″-sulfate	Structural Classification Flavonoids Classification of Application Fields Flavanols Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	Endogenous Metabolite Apoptosis
EGCG-4″-sulfate is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate sulfate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. EGCG-4″-sulfate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-13653R

(-)-Epigallocatechin Gallate (Standard) Maximum Cited Publications 29 Publications Verification EGCG(Standard); Epigallocatechol Gallate (Standard)	Structural Classification Flavonoids other families Classification of Application Fields Anti-aging Source classification Phenols Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	Endogenous Metabolite Apoptosis
(-)-Epigallocatechin Gallate (Standard) is the analytical standard of (-)-Epigallocatechin Gallate. This product is intended for research and analytical applications. (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-N10264

Avrainvillamide (+)-Avrainvillamide; CJ-17,665	Infection Alkaloids Structural Classification Microorganisms Pyrrole Alkaloids Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Antibiotic
Avrainvillamide ((+)-Avrainvillamide) is a naturally occurring alkaloid with antiproliferative effects, binds to the nuclear chaperone nucleophosmin, a proposed oncogenic protein that is overexpressed in many different human tumors. Avrainvillamide affects cell biology both by directly binding NPM1 and Crm1 as well as by inhibiting the association of these proteins with certain native cellular partners. Avrainvillamide, an antibiotic, inhibits growth of multi-agent resistant Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, with MICs of 12.5, 12.5 and 25 μg/ml, respectively .

Species:	Human (23) Rhesus Macaque (2) Mouse (8) Cynomolgus (1)
Tag:	His (23) Tag Free (5) Strep (1) GST (3) Fc (4) Flag (2)
Source:	HEK293 (23) E. coli (11)

Cat. No.	Compare	Product Name	Species	Source

HY-P702056

	MYD88 Protein, Human MYD88; myeloid differentiation primary response protein MyD88	Human	E. coli
	The MYD88 protein is a key adapter in Toll-like receptor (TLR) and IL-1 receptor signaling and can activate NF-kappa-B, cytokine secretion and inflammatory responses through IRAK1, IRAK2, IRF7 and TRAF6. It enhances IL-8 transcription and participates in IL-18-mediated pathways. MYD88 Protein, Human is the recombinant human-derived MYD88 protein, expressed by E. coli , with tag free. The total length of MYD88 Protein, Human is 140 a.a., .

HY-P702057

	MYD88 Protein, Human (His, GST) MYD88; myeloid differentiation primary response protein MyD88	Human	E. coli
	The MYD88 protein is a key adapter in Toll-like receptor (TLR) and IL-1 receptor signaling and can activate NF-kappa-B, cytokine secretion and inflammatory responses through IRAK1, IRAK2, IRF7 and TRAF6. It enhances IL-8 transcription and participates in IL-18-mediated pathways. MYD88 Protein, Human (His, GST) is the recombinant human-derived MYD88 protein, expressed by E. coli , with N-6*His, N-GST labeled tag. The total length of MYD88 Protein, Human (His, GST) is 140 a.a., .

HY-P73641

	Siglec-3/CD33 Protein, Mouse (HEK293) myeloid Cell Surface Antigen CD33; Siglec-3; gp67; CD33; SIGLEC3	Mouse	HEK293
	Siglec-3/CD33, a sialic-acid-binding lectin, crucially mediates cell-cell interactions and immune cell quiescence. Preferring sialic acid on specific mucins, it forms homodimers, interacting with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. CD33 also engages C1QA through its C-terminus, activating CD33 inhibitory motifs. Siglec-3/CD33 Protein, Mouse (HEK293) is the recombinant mouse-derived Siglec-3/CD33 protein, expressed by HEK293 , with tag free. The total length of Siglec-3/CD33 Protein, Mouse (HEK293) is 240 a.a., with molecular weight of ~25.6 kDa.

HY-P73643

	Siglec-3/CD33 Protein, Human (HEK293) myeloid Cell Surface Antigen CD33; Siglec-3; gp67; CD33; SIGLEC3	Human	HEK293
	Siglec-3/CD33, a sialic-acid-binding lectin, crucially mediates cell-cell interactions and immune cell quiescence. Preferring sialic acid on specific mucins, it forms homodimers, interacting with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. CD33 also engages C1QA through its C-terminus, activating CD33 inhibitory motifs. Siglec-3/CD33 Protein, Human (HEK293) is the recombinant human-derived Siglec-3/CD33 protein, expressed by HEK293 , with tag free. The total length of Siglec-3/CD33 Protein, Human (HEK293) is 242 a.a., with molecular weight of ~27.4 kDa.

HY-P7786

	CD14 Protein, Human (HEK293, His) rHuCD14, His; Monocyte Differentiation Antigen CD14; myeloid Cell-Specific Leucine-Rich Glycoprotein; CD14	Human	HEK293
	CD14 Protein, Human (HEK293, His) is a recombinant human CD14 expressed in HEK 293 cells with a His tag at the N-terminus. CD14 Protein is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes.

HY-P73531

	CD14 Protein, Mouse (HEK293, His) rHuCD14, His; Monocyte Differentiation Antigen CD14; myeloid Cell-Specific Leucine-Rich Glycoprotein; CD14	Mouse	HEK293
	CD14 protein is a key protein in the innate immune response and is significantly expressed in monocytes/macrophages. It acts as a coreceptor that binds various microbial and fungal molecules, including lipopolysaccharide (LPS). CD14 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD14 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD14 Protein, Mouse (HEK293, His) is 330 a.a., with molecular weight of ~45-50 kDa.

HY-P73639

	Siglec-3/CD33 Protein, Mouse (HEK293, His) myeloid Cell Surface Antigen CD33; Siglec-3; gp67; CD33; SIGLEC3	Mouse	HEK293
	Siglec-3/CD33, a sialic-acid-binding lectin, crucially mediates cell-cell interactions and immune cell quiescence. Preferring sialic acid on specific mucins, it forms homodimers, interacting with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. CD33 also engages C1QA through its C-terminus, activating CD33 inhibitory motifs. Siglec-3/CD33 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Siglec-3/CD33 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-3/CD33 Protein, Mouse (HEK293, His) is 240 a.a., with molecular weight of 38-42 kDa.

HY-P73640

	Siglec-3/CD33 Protein, Mouse (HEK293, Fc) myeloid Cell Surface Antigen CD33; Siglec-3; gp67; CD33; SIGLEC3	Mouse	HEK293
	Siglec-3/CD33, a sialic-acid-binding lectin, crucially mediates cell-cell interactions and immune cell quiescence. Preferring sialic acid on specific mucins, it forms homodimers, interacting with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. CD33 also engages C1QA through its C-terminus, activating CD33 inhibitory motifs. Siglec-3/CD33 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Siglec-3/CD33 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Siglec-3/CD33 Protein, Mouse (HEK293, Fc) is 240 a.a., with molecular weight of 55-60 kDa.

HY-P73642

	Siglec-3/CD33 Protein, Human (HEK293, hFc) myeloid Cell Surface Antigen CD33; Siglec-3; gp67; CD33; SIGLEC3	Human	HEK293
	Siglec-3/CD33 protein is a sialic acid-binding lectin that mediates cell-cell interactions and maintains immune cell quiescence. It prefers α-2,3- and α-2,6-linked glycans with sialic acid. Siglec-3/CD33 Protein, Human (HEK293, hFc) is the recombinant human-derived Siglec-3/CD33 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Siglec-3/CD33 Protein, Human (HEK293, hFc) is 242 a.a., with molecular weight (glycosylation form) of 68-80 kDa.

HY-P73644

	Siglec-3/CD33 Protein, Human (HEK293, His) myeloid Cell Surface Antigen CD33; Siglec-3; gp67; CD33; SIGLEC3	Human	HEK293
	Siglec-3/CD33, a sialic-acid-binding lectin, crucially mediates cell-cell interactions and immune cell quiescence. Preferring sialic acid on specific mucins, it forms homodimers, interacting with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. CD33 also engages C1QA through its C-terminus, activating CD33 inhibitory motifs. Siglec-3/CD33 Protein, Human (HEK293, His) is the recombinant human-derived Siglec-3/CD33 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-3/CD33 Protein, Human (HEK293, His) is 242 a.a., with molecular weight of 40-46 kDa.

HY-P77536

	Siglec-3/CD33 Protein, Human (Biotinylated, HEK293, His) myeloid Cell Surface Antigen CD33; Siglec-3; gp67; CD33; SIGLEC3	Human	HEK293
	Siglec-3/CD33, a sialic-acid-binding lectin, crucially mediates cell-cell interactions and immune cell quiescence. Preferring sialic acid on specific mucins, it forms homodimers, interacting with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. CD33 also engages C1QA through its C-terminus, activating CD33 inhibitory motifs. Siglec-3/CD33 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Siglec-3/CD33 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-3/CD33 Protein, Human (Biotinylated, HEK293, His) is 242 a.a., with molecular weight of ~28.2 KDa.

HY-P75651

	Siglec-3/CD33 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) myeloid Cell Surface Antigen CD33; Siglec-3; gp67; CD33; SIGLEC3	Rhesus Macaque	HEK293
	Siglec-3/CD33, a sialic-acid-binding lectin, crucially mediates cell-cell interactions and immune cell quiescence. Preferring sialic acid on specific mucins, it forms homodimers, interacting with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. CD33 also engages C1QA through its C-terminus, activating CD33 inhibitory motifs. Siglec-3/CD33 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived Siglec-3/CD33 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-3/CD33 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is 233 a.a., with molecular weight of ~45.2 kDa.

HY-P75652

	Siglec-3/CD33 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) myeloid Cell Surface Antigen CD33; Siglec-3; gp67; CD33; SIGLEC3	Rhesus Macaque	HEK293
	Siglec-3/CD33, a sialic-acid-binding lectin, crucially mediates cell-cell interactions and immune cell quiescence. Preferring sialic acid on specific mucins, it forms homodimers, interacting with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. CD33 also engages C1QA through its C-terminus, activating CD33 inhibitory motifs. Siglec-3/CD33 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is the recombinant Rhesus Macaque-derived Siglec-3/CD33 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-3/CD33 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is 248 a.a., with molecular weight of ~27.3 kDa.

HY-P70581

	MYDGF Protein, Human (His) UPF0556 protein C19orf10; stromal cell-derived growth factor SF20; C19orf10; myeloid-derived growth factor; MYDGF	Human	E. coli
	The MYDGF protein is derived from bone marrow mononuclear cells and significantly promotes cardioprotection and post-myocardial infarction (MI) repair. Its functions include promoting cardiomyocyte survival and promoting adaptive angiogenesis. MYDGF Protein, Human (His) is the recombinant human-derived MYDGF protein, expressed by E. coli , with N-6*His labeled tag. The total length of MYDGF Protein, Human (His) is 141 a.a., with molecular weight of ~17.0 kDa.

HY-P72472

	Siglec-3/CD33 Protein, Human (HEK293, Fc-His) myeloid Cell Surface Antigen CD33; Sialic Acid-Binding Ig-Like Lectin 3; Siglec-3; gp67; CD33; SIGLEC3	Human	HEK293
	Siglec-3/CD33, a sialic-acid-binding lectin, crucially mediates cell-cell interactions and immune cell quiescence. Preferring sialic acid on specific mucins, it forms homodimers, interacting with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. CD33 also engages C1QA through its C-terminus, activating CD33 inhibitory motifs. Siglec-3/CD33 Protein, Human (HEK293, Fc-His) is the recombinant human-derived Siglec-3/CD33 protein, expressed by HEK293 , with C-hFc, C-6*His labeled tag. The total length of Siglec-3/CD33 Protein, Human (HEK293, Fc-His) is 242 a.a., with molecular weight of ~80 kDa.

HY-P701589

	KMT2D Protein, Human KMT2D; Histone-lysine N-methyltransferase 2D; Lysine N-methyltransferase 2D; ALL1-related protein; myeloid/lymphoid or mixed-lineage leukemia protein 2	Human	E. coli
	KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human is the recombinant human-derived KMT2D protein, expressed by E. coli , with tag free. The total length of KMT2D Protein, Human is 155 a.a., .

HY-P701590

	KMT2D Protein, Human (GST) KMT2D; Histone-lysine N-methyltransferase 2D; Lysine N-methyltransferase 2D; ALL1-related protein; myeloid/lymphoid or mixed-lineage leukemia protein 2	Human	E. coli
	KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human (GST) is the recombinant human-derived KMT2D protein, expressed by E. coli , with N-GST labeled tag. The total length of KMT2D Protein, Human (GST) is 155 a.a., .

HY-P72473

	Siglec-3/CD33 Protein, Mouse (G236R, HEK293, His) myeloid Cell Surface Antigen CD33; Sialic Acid-Binding Ig-Like Lectin 3; Siglec-3; gp67; CD33; SIGLEC3	Mouse	HEK293
	Siglec-3/CD33, a sialic-acid-binding lectin, crucially mediates cell-cell interactions and immune cell quiescence. Preferring sialic acid on specific mucins, it forms homodimers, interacting with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. CD33 also engages C1QA through its C-terminus, activating CD33 inhibitory motifs. Siglec-3/CD33 Protein, Mouse (G236R, HEK293, His) is the recombinant mouse-derived Siglec-3/CD33 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Siglec-3/CD33 Protein, Mouse (G236R, HEK293, His) is 223 a.a., with molecular weight of 30-45 kDa.

HY-P72171

	DEFA1 Protein, Human (GST) alpha 1; DEF1; DEF1_HUMAN; DEFA1; DEFA1B; DEFA2; Defensin 1; Defensin; Defensin; alpha 1; Defensin; alpha 1; myeloid related sequence; Defensin; alpha 2; HNP-1; HNP-2; HNP1; HP-1; HP-2; HP1; HP2; MRS; myeloid related sequence; Neutrophil defensin 1; Neutrophil defensin 2	Human	E. coli
	The DEFA1 protein is a multifunctional effector in innate immunity that exhibits antibiotic-like properties against bacteria, fungi, and viruses. It promotes immune defense by activating antigen-presenting cells (APCs) and inhibiting bacterial cell wall synthesis by interacting with lipid II. DEFA1 Protein, Human (GST) is the recombinant human-derived DEFA1 protein, expressed by E. coli , with N-GST labeled tag. The total length of DEFA1 Protein, Human (GST) is 94 a.a., with molecular weight of ~34 kDa.

HY-P7765

	MPIF-1/CCL23 Protein, Human (75a.a) rHuCCL23; C-C Motif Chemokine 23; CKB-8; Macrophage Inflammatory Protein 3; MIP-3; myeloid Progenitor Inhibitory Factor 1; MPIF-1; CCL23; MIP3; MPIF1; SCYA23	Human	E. coli
	MPIF-1/CCL23 protein, Human (75a.a), a CC chemokine, is highly chemotactic for resting T cells and monocytes, mediates inflammatory and immune responses by binding to the chemokine receptor CCR1, inhibits myeloid progenitor cell formation, and has some pro-cancer effects. MPIF-1/CCL23 Protein, Human (75a.a) is a recombinant human MPIF-1/CCL23 (R46-N120) protein expressed by E. coli.

HY-P7766

	CCL24/Eotaxin-2 Protein, Human (HEK293, His) rHuCCL24, His; C-C motif chemokine 24 ; CCL24; Eosinophil chemotactic protein; Eotaxin-2; myeloid progenitor inhibitory factor 2; Small-inducible cytokine A24; Ckb-6; MPIF-2; SCYA24	Human	HEK293
	CCL24/Eotaxin-2 Protein, Human (HEK293, His) is a CC chemokine that interacts with the chemokine receptor CCR3 to induce eosinophil chemotaxis and mediate atopic diseases, parasitic infections and systemic diseases, as well as promote cellular transport and regulate inflammatory and fibrotic activities. CCL24/Eotaxin-2 Protein, Human (HEK293, His) is a recombinant human CCL24/Eotaxin-2 (V27-C119) protein expressed by HEK293 with a his tag.

HY-P70212

	GADD45B Protein, Human (His) rHuGrowth arrest and DNA damage-inducible protein GADD45 beta/GADD45B, His; Growth Arrest and DNA Damage-Inducible Protein GADD45 Beta; myeloid Differentiation Primary Response Protein MyD118; Negative Growth Regulatory Protein MyD118; GADD45B; MYD118	Human	E. coli
	GADD45B Protein, a pivotal mediator, regulates growth and apoptosis by activating the MTK1/MEKK4 MAPKKK signaling pathway. Interacting with GADD45GIP1, it forms a complex that modulates cellular responses under stress. Its central role in growth and apoptosis underscores its significance in orchestrating cellular processes, positioning GADD45B as a key player in the intricate network of signaling pathways governing cell fate decisions. GADD45B Protein, Human (His) is the recombinant human-derived GADD45B protein, expressed by E. coli , with N-6*His labeled tag. The total length of GADD45B Protein, Human (His) is 160 a.a., with molecular weight of ~24.0 kDa.

HY-P71381

	TREM-2 Protein, Mouse (HEK293, His) Triggering Receptor Expressed on myeloid Cells 2b; Triggering receptor expressed on myeloid cells 2; TREM-2; Triggering receptor expressed on monocytes 2; Trem2; Trem2a; Trem2b; Trem2c; TREM-2b	Mouse	HEK293
	TREM-2 protein forms a signaling complex with TYROBP, activates cells upon ligand binding, and acts as a receptor for amyloid beta, lipoproteins, and apolipoproteins. It promotes their uptake by microglia, triggering activation, proliferation, migration, apoptosis and cytokine expression. TREM-2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived TREM-2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TREM-2 Protein, Mouse (HEK293, His) is 150 a.a., with molecular weight of 25-40 kDa.

HY-P70716

	TREM-1 Protein, Mouse (HEK293, His) Triggering receptor expressed on myeloid cells 1; TREM-1; CD354; Trem1	Mouse	HEK293
	The TREM-1 protein is a key cell surface receptor that amplifies inflammatory responses in innate and adaptive immunity. Ligands such as PGLYRP1, HMGB1 or HSP70 activate TREM-1, leading to multimerization and complex formation with TYROBP/DAP12. TREM-1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived TREM-1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TREM-1 Protein, Mouse (HEK293, His) is 182 a.a., with molecular weight of ~38.0 kDa.

HY-P72438

	TREM-2 Protein, Cynomolgus (HEK293, His) Ig-like domain-containing protein; TREM2; Triggering receptor expressed on myeloid cells 2	Cynomolgus	HEK293
	TREM-2 protein forms a signaling complex with TYROBP, activates cells upon ligand binding, and acts as a receptor for amyloid beta, lipoproteins, and apolipoproteins. It promotes their uptake by microglia, triggering activation, proliferation, migration, apoptosis and cytokine expression. TREM-2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TREM-2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TREM-2 Protein, Cynomolgus (HEK293, His) is 156 a.a., with molecular weight of 28-40 kDa.

HY-P701996

	IFI16 Protein, Human (FLAG) IFI16; Gamma-interferon-inducible protein 16; Ifi-16; Interferon-inducible myeloid differentiation transcriptional activator	Human	E. coli
	The IFI16 protein prefers supercoiled and cruciform DNA structures, regulates transcription, and may act as a repressor protein, affecting hematopoietic differentiation and controlling cell proliferation. It regulates key cell cycle factors such as p53/TP53 and participates in the energy-dependent ATM/AMPK/TP53 pathway to regulate autophagy. IFI16 Protein, Human (FLAG) is the recombinant human-derived IFI16 protein, expressed by E. coli , with C-Flag labeled tag. The total length of IFI16 Protein, Human (FLAG) is 729 a.a., .

HY-P701997

	IFI16 Protein, Human (His, Strep) IFI16; Gamma-interferon-inducible protein 16; Ifi-16; Interferon-inducible myeloid differentiation transcriptional activator	Human	E. coli
	The IFI16 protein prefers supercoiled and cruciform DNA structures, regulates transcription, and may act as a repressor protein, affecting hematopoietic differentiation and controlling cell proliferation. It regulates key cell cycle factors such as p53/TP53 and participates in the energy-dependent ATM/AMPK/TP53 pathway to regulate autophagy. IFI16 Protein, Human (His, Strep) is the recombinant human-derived IFI16 protein, expressed by E. coli , with N-Strep, N-6*His labeled tag. The total length of IFI16 Protein, Human (His, Strep) is 729 a.a., .

HY-P70534

	TREM-2 Protein, Human (HEK293, His) Triggering receptor expressed on myeloid cells 2; TREM-2; Triggering receptor expressed on monocytes 2; TREM2	Human	HEK293
	TREM-2 Protein is a receptor for amyloid beta protein 42, lipoprotein particles, and apolipoprotein. TREM-2 Protein is involved in cell proliferation and apoptosis through Wnt/β, MTOR, PI3K and NF-kappa-B signaling pathways. TREM-2 Protein is expressed by macrophages, immature monocyte-derived dendritic cells, osteoclasts, and microglia to activate the immune response. TREM-2 Protein, Human (HEK293, His) is the recombinant human-derived TREM-2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TREM-2 Protein, Human (HEK293, His) is 156 a.a., with molecular weight of 22-40 kDa.

HY-P71384

	TREML2 Protein, Mouse (HEK293, His) Trem-like transcript 2 protein; TLT-2; Triggering receptor expressed on myeloid cells-like protein 2; TREML2; TLT2	Mouse	HEK293
	TREML2 protein acts as a cell surface receptor for SEMA6A and affects key intercellular signaling in cerebellar development. It regulates granule cell migration, coordinates actin cytoskeletal reorganization, and contributes significantly to axonal guidance in the central nervous system. TREML2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived TREML2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TREML2 Protein, Mouse (HEK293, His) is 246 a.a., with molecular weight of 58-62 kDa.

HY-P71380

	TREM-1 Protein, Human (180a.a, HEK293, His) Triggering Receptor Expressed on myeloid Cells 1; TREM-1; Triggering Receptor Expressed on Monocytes 1; CD354; TREM1	Human	HEK293
	The TREM-1 protein is a cell surface receptor that critically regulates innate and adaptive immunity by enhancing inflammatory responses. TREM-1 plays a crucial role in acute and chronic inflammatory diseases, acting as a decoy receptor to balance its pro-inflammatory effects. TREM-1 Protein, Human (180a.a, HEK293, His) is the recombinant human-derived TREM-1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TREM-1 Protein, Human (180a.a, HEK293, His) is 180 a.a., with molecular weight of 26-40 kDa.

HY-P71383

	TREML2 Protein, Human (HEK293, Fc) Trem-like transcript 2 protein; TLT2; Triggering receptor expressed on myeloid cells-like protein 2; TLT2; C6orf76;	Human	HEK293
	TREML2 protein acts as a cell surface receptor, interacting with CD276 on T-cells to enhance T-cell activation and modulate immune responses, particularly in regulating T-cell activation during immune reactions. TREML2 Protein, Human (HEK293, Fc) is the recombinant human-derived TREML2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TREML2 Protein, Human (HEK293, Fc) is 250 a.a., with molecular weight of 80-110 kDa.

HY-P71382

	TREML1 Protein, Human (147a.a, HEK293, His) Trem-Like Transcript 1 Protein; TLT-1; Triggering Receptor Expressed on myeloid Cells-Like Protein 1; TREML1; TLT1	Human	HEK293
	TREML1 (triggering receptor expressed on myeloid cells, like 1) is a cell surface receptor that may play a role in innate and adaptive immune responses. When phosphorylated, TREML1 interacts with the proteins PTPN6 and PTPN11, suggesting that it may be involved in regulating signaling pathways related to immune processes. TREML1 Protein, Human (147a.a, HEK293, His) is the recombinant human-derived TREML1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TREML1 Protein, Human (147a.a, HEK293, His) is 147 a.a., with molecular weight of ~20.0 kDa.

HY-P71259

	Resistin Protein, Human (His) 1 Publications Verification Resistin; Adipose tissue-specific secretory factor; Cysteine-rich secreted protein FIZZ3; C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein; Cysteine-rich secreted protein A12-alpha-like 2; FIZZ3; HXCP1; RSTN; RETN	Human	E. coli
	Resistin, a hormone linking obesity to diabetes, may hinder insulin's glucose uptake stimulation in adipose cells, contributing to metabolic dysregulation. Additionally, it promotes myeloid cell chemotaxis and forms homodimers through disulfide linkages, interacting with DEFA1. Resistin's involvement in diverse cellular processes suggests its pivotal role in the complex interplay of metabolism, inflammation, and insulin responsiveness. Resistin Protein, Human (His) is the recombinant human-derived Resistin protein, expressed by E. coli , with C-6*His labeled tag. The total length of Resistin Protein, Human (His) is 90 a.a., with molecular weight of 10-14 kDa.

HY-P70080

	CLM9/CD300g Protein, Human (229a.a, HEK293, His) rHuCMRF35-like molecule 9/Clm-9, His; CMRF35-Like Molecule 9; CLM-9; CD300 Antigen-Like Family Member G; Triggering Receptor Expressed on myeloid Cells 4; TREM-4; CD300g; CD300LG; CLM9; TREM4	Human	HEK293
	The CLM9/CD300g protein is known as a receptor and is thought to be involved in mediating L-selectin-dependent lymphocyte rolling. This protein exhibits calcium-dependent binding to SELL (L-selectin ligand), indicating its ability to interact with lymphocytes and potentially influence lymphocyte-related processes. CLM9/CD300g Protein, Human (229a.a, HEK293, His) is the recombinant human-derived CLM9/CD300g protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CLM9/CD300g Protein, Human (229a.a, HEK293, His) is 229 a.a., with molecular weight of ~64.0 kDa.

Cat. No.	Product Name	Chemical Structure

HY-153939S

Idasanutlin-d3-1
Idasanutlin-d₃-1 (RG7388-d₃-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of MDM2/p53. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia .

HY-50907S

ABT-737-d8

ABT 737-d₈ is the deuterium labeled ABT-737. ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks